Ken Frazier

EconomyMIT Technology Review

Ken Frazier: Our democracy only works if everyone has opportunity

Merck CEO and OneTen cofounder Ken Frazier knows the critical importance to a company’s success of getting the right people in the right jobs. On June 8, Frazier joined MIT Technology Review’s virtual EmTech Next, our annual future-of-work event, to share how businesses can reduce the opportunity gap to find the skilled workforce they need, and why CEOs need to speak up on issues if they want their organizations to stay competitive.

Merck’s Ken Frazier Named CEO of the Year

Merck Chief Executive Officer Kenneth Frazier has been named CEO of the Year by Chief Executive magazine for his longtime leadership at the pharmaceutical giant. Frazier, who will retire from his role at Merck at the end of June, was selected for the honor by an independent committee, Black Enterprise reported. He was tapped for his leadership skills that have guided the company and expanded its influence in oncology, particularly with the powerhouse checkpoint inhibitor Keytruda and his influence in developing the company’s discovery research programs. In addition to his guidance of Merck, Frazier was also selected CEO of the Year for his devotion to social justice and economic inclusion.
Picture for Merck’s Ken Frazier Named CEO of the Year
New York City, NYPosted by
Black Enterprise

Merck Executive Ken Frazier Named Chief Executive’s 2021 CEO Of The Year

Chief Executive magazine has named Merck CEO Black corporate executive Kenneth Frazier as its 2021 CEO of the year. Frazier was selected for the award by an independent committee that has recognized his team leadership skills and his unprecedented work at Merck over the past decade. Since Frazier was appointed CEO and chairman of Merck in 2011 he has made significant changes, especially early research.
POTUSPosted by

Merck CEO Ken Frazier is stepping down

Merck’s Ken Frazier, one of just five Black CEOs in the Fortune 500, will retire on June 30. Why it matters: His departure leaves just 3 Black people atop America’s 500 largest companies (assuming no other Black chiefs are named by then). Details: Robert Davis, the company’s CFO and a...

Ken Frazier to step down as Merck CEO

Merck CEO Ken Frazier will retire effective June 30 and will be replaced with the company’s CFO Robert Davis, the company announced on Thursday. CNBC's "Squawk Box" crew discusses.
POTUSPosted by

One of the few top U.S. Black CEOs, Merck's Ken Frazier to retire

(Reuters) - Merck & Co Inc said on Thursday Ken Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis. Frazier, 66, will remain with the...

Rare black Fortune 500 chief Ken Frazier to retire

The US is losing one of its few black leaders at the top of a major American company. Merck & Co's chief executive Kenneth Frazier is retiring at the end of June, the drugs company said. The firm said he would be replaced by current chief financial officer Robert Davis,...
POTUSPosted by

Ken Frazier, one of the only Black Fortune 500 CEOs, is retiring

New York (CNN Business) — Merck CEO Kenneth Frazier, who is currently one of the few Black CEOs of a Fortune 500 company, is retiring in June, ending a nearly 30-year run with the company. The pharmaceutical giant announced the change Thursday, naming Chief Financial Officer Robert Davis as its...
Kenilworth, NJABC News

Longtime Merck CEO, minority advocate Ken Frazier to retire

Longtime Merck executive Ken Frazier, one of the few remaining Black CEOs of a Fortune 500 company, is retiring. Kenilworth, NJ -- Longtime Merck executive Ken Frazier, whose leadership helped bring the drugmaker one of the most lucrative medicines in history and who is one of the few remaining Black CEOs of a major corporation, is retiring.

Merck CEO Ken Frazier retiring; Rob Davis named as successor

Merck is again promoting from within, naming Robert Davis to fill the CEO role after Kenneth Frazier's departure. © 2021 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement (updated 1/1/21) and Privacy Policy and Cookie Statement (updated 1/1/21). The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of American City Business Journals.

Merck Posts Steady Q4; CEO Ken Frazier to Retire

Merck (MRK) reported fourth-quarter results largely in line with our expectations, and we don’t expect any major changes to our fair value estimate. We continue to view the company as undervalued with the market not fully appreciating the firm’s growth potential, largely driven by cancer drug Keytruda in new indications, which should add high-margin sales and expand profit margins.